Novozymes Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Novozymes wird ein jährliches Gewinn- und Umsatzwachstum von 19.5% bzw. 12.3% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 11.4% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 8.1% betragen.

Wichtige Informationen

19.5%

Wachstumsrate der Gewinne

11.4%

EPS-Wachstumsrate

Chemicals Gewinnwachstum	51.6%
Wachstumsrate der Einnahmen	12.3%
Zukünftige Eigenkapitalrendite	8.1%
Analystenabdeckung	Good
Zuletzt aktualisiert	09 Apr 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

BMV:NSIS N - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (DKK Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	33,658	6,486	6,373	9,589	7
12/31/2025	31,457	5,531	5,222	8,381	7
12/31/2024	29,428	4,245	4,061	6,573	7
12/31/2023	17,899	3,024	2,097	4,152	N/A
9/30/2023	17,825	3,209	1,263	3,614	N/A
6/30/2023	17,736	3,425	616	3,248	N/A
3/31/2023	17,805	3,628	618	3,545	N/A
12/31/2022	17,553	3,676	1,116	4,006	N/A
9/30/2022	16,858	3,418	1,528	4,117	N/A
6/30/2022	16,252	3,108	1,946	4,007	N/A
3/31/2022	15,546	3,093	2,504	3,939	N/A
12/31/2021	14,951	3,146	2,822	4,062	N/A
9/30/2021	14,563	3,175	3,428	4,413	N/A
6/30/2021	14,233	3,044	3,209	4,197	N/A
3/31/2021	14,002	2,895	3,293	4,290	N/A
12/31/2020	14,012	2,825	3,415	4,355	N/A
9/30/2020	14,297	3,093	3,294	3,881	N/A
6/30/2020	14,570	3,020	3,463	3,997	N/A
3/31/2020	14,679	3,273	3,035	3,596	N/A
12/31/2019	14,374	3,154	2,629	3,196	N/A
9/30/2019	14,357	3,069	2,358	3,436	N/A
6/30/2019	14,311	3,238	2,616	3,768	N/A
3/31/2019	14,351	3,116	2,305	3,558	N/A
12/31/2018	14,390	3,226	2,287	3,679	N/A
9/30/2018	14,349	3,183	2,258	3,839	N/A
6/30/2018	14,271	3,194	1,954	3,649	N/A
3/31/2018	14,311	3,154	2,048	3,738	N/A
12/31/2017	14,531	3,119	2,371	4,063	N/A
9/30/2017	14,572	3,131	N/A	3,963	N/A
6/30/2017	14,382	3,063	N/A	3,883	N/A
3/31/2017	14,273	3,077	N/A	4,073	N/A
12/31/2016	14,142	3,050	N/A	3,840	N/A
9/30/2016	13,880	2,936	N/A	3,632	N/A
6/30/2016	14,012	2,929	N/A	3,248	N/A
3/31/2016	14,032	2,861	N/A	3,353	N/A
12/31/2015	14,002	2,823	N/A	3,339	N/A
9/30/2015	13,731	2,734	N/A	2,945	N/A
6/30/2015	13,393	2,630	N/A	3,308	N/A
3/31/2015	13,005	2,539	N/A	3,391	N/A
12/31/2014	12,459	2,526	N/A	4,525	N/A
9/30/2014	12,218	2,484	N/A	5,061	N/A
6/30/2014	11,970	2,413	N/A	4,791	N/A
3/31/2014	11,934	2,379	N/A	4,235	N/A
12/31/2013	11,746	2,200	N/A	2,599	N/A
9/30/2013	11,617	2,132	N/A	2,547	N/A
6/30/2013	11,519	2,085	N/A	2,531	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: NSIS NDas prognostizierte Gewinnwachstum (19.5% pro Jahr) liegt über der Sparquote (7.7%).

Ertrag vs. Markt: NSIS NDie Erträge des Unternehmens (19.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt MX (11.2% pro Jahr).

Hohe Wachstumserträge: NSIS NDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: NSIS NDie Einnahmen des Unternehmens (12.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt MX (7.1% pro Jahr).

Hohe Wachstumseinnahmen: NSIS NDie Einnahmen des Unternehmens (12.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: NSIS NDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (8.1 %).

Novozymes Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Novonesis Provides Sales Guidance for the Year 2024

Novonesis Provides Earnings Guidance for the Year 2024

Novozymes A/S Provides Earnings Guidance for the Year 2023

Novozymes A/S Provides Earnings Guidance for the Year 2022

Novozymes A/S Provides Earnings Guidance for the Year 2022

Novozymes A/S Raises Full-Year Financial Guidance for 2022

Recent updates

Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Less than half of directors are independent

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches Quara(R) Lowp for Renewable Diesel Feedstock Pre-T Treatment

Investor sentiment improves as stock rises 18%

Less than half of directors are independent

Novozymes Launches ProSilience™ HU58

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Novozymes A/S Announces Change to the Executive Leadership Team

First quarter 2023 earnings released: EPS: kr.2.83 (vs kr.3.00 in 1Q 2022)

Less than half of directors are independent

Investor sentiment deteriorates as stock falls 17%

Less than half of directors are independent

Novozymes A/S Provides Earnings Guidance for the Year 2023

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Less than half of directors are independent

Third quarter 2022 earnings released

Novozymes A/S Provides Earnings Guidance for the Year 2022

Biotalys Nv and Novozymes A/S Announces Successful Evoca™ Feasibility Study

Less than half of directors are independent

Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022

Less than half of directors are independent

Second quarter 2022 earnings released: EPS: kr.2.92 (vs kr.2.85 in 2Q 2021)

Less than half of directors are independent

Novozymes A/S Provides Earnings Guidance for the Year 2022

Novozymes A/S to Report Nine Months, 2023 Results on Oct 26, 2023

Novozymes Extends the Lifetime of Textiles with Sustainable Innovation

Less than half of directors are independent

First quarter 2022 earnings released: EPS: kr.3.00 (vs kr.3.17 in 1Q 2021)

Less than half of directors are independent

Novozymes A/S Raises Full-Year Financial Guidance for 2022

Less than half of directors are independent

Upcoming dividend of kr.5.50 per share

Less than half of directors are independent

Less than half of directors are independent

Novozymes A/S Provides Revenue Guidance for 2022

Less than half of directors are independent

Novozymes A/S (CPSE:NZYM B) completed the acquisition of a 60% stake in Synergia Life Sciences Pvt. Ltd. for DKK 1 billion.

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Novozymes A/S Provides Earnings Guidance for the Full Year 2021

First quarter 2021 earnings released: EPS kr.3.17 (vs kr.2.89 in 1Q 2020)

Novozymes A/S Reaffirms Sales Guidance for the Year 2021

Univar Solutions and Novozymes® Partner to Bring Innovative, Sustainable Biotechnology Products to Customers in the United States and Canada

Novozymes Acquires Data Science Platform of Biota to Strengthen Microbiome R&D Capabilities in Probiotic Development

Novozymes A/S (CPSE:NZYM B) acquired the Microbiome R&D Team and Data Science Platform from Biota Technology, Inc.

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken